Aurobindo Pharma is intensifying its focus on biosimilars with an extensive array of products. The company is implementing a dual strategy in the biosimilars market, which involves both innovative product development and contract manufacturing. Through its subsidiary, CuraTeQ Biologics, the brand is concentrating on biosimilars in oncology and immunology.
CuraTeQ’s pipeline includes fourteen biosimilars, aimed at ensuring sustainable growth and long term value. The company has received marketing authorization for trastuzumab from Indian regulators and plans to launch it domestically in FY25.
Additionally, Aurobindo Pharma’s omalizumab biosimilar, which targets Xolair, has successfully met the pharmacokinetics and pharmacodynamics endpoints in a three-arm phase one clinical study. The pipeline encompasses therapeutic areas such as oncology, ophthalmology, immunology, and respiratory conditions.
Nithyananda Reddy, Vice-Chairman and Managing Director of Aurobindo Pharma stated, “We will continue to invest in R&D, expansion of production capacity, and capability enhancement projects, including biosimilars and biologics contract manufacturing. These investments are expected to drive our growth”.
With its newly operational manufacturing units, Aurobindo Pharma is optimistic about maintaining its growth trajectory, enhancing self-reliance, and achieving sustainable top-line and bottom-line improvements.
As reported by thehindubusinessline.com, recently, the company, through its wholly-owned subsidiary TheraNym Biologics, ventured into biologics contract manufacturing. Aurobindo Pharma is planning to establish a biologics manufacturing facility with an annual capacity of 25-30 million vials, at an investment of up to ₹1,000 crore.
